Polycystic Ovarian Syndrome (PCOS)

01Pathophysiology

PCOS originates from a disruption in the hypothalamic-pituitary-ovarian axis. In a normal cycle, pulsatile GnRH release from the hypothalamus drives balanced secretion of LH and FSH from the anterior pituitary, which in turn coordinates follicular maturation, ovulation, and corpus luteum formation. In PCOS, the GnRH pulse frequency is abnormally increased, which preferentially stimulates LH secretion over FSH. This results in a tonically elevated LH level with relatively suppressed FSH.

The elevated LH drives ovarian theca cells to produce excess androgens (primarily androstenedione and testosterone). Under normal conditions, FSH would stimulate granulosa cells to convert these androgens into estrogens via aromatase. However, because FSH is relatively low, aromatase activity is insufficient, and androgens accumulate. This excess androgen is the direct cause of hirsutism, acne, and androgenic alopecia seen on exam.

The follicular development process is also disrupted. Without adequate FSH, multiple small antral follicles begin to develop but none reaches dominance or ovulates. These arrested follicles line the ovarian cortex, producing the characteristic "string of pearls" appearance on ultrasound. Because ovulation fails to occur, there is chronic anovulation, which explains the oligomenorrhea or amenorrhea.

Insulin resistance plays a central amplifying role. Hyperinsulinemia directly stimulates ovarian androgen production and simultaneously decreases hepatic production of sex hormone-binding globulin (SHBG). Lower SHBG means more free (bioavailable) testosterone circulates, worsening hyperandrogenic symptoms even if total testosterone is only mildly elevated. This is why acanthosis nigricans (a marker of insulin resistance) frequently appears on physical exam and serves as an important clue.

The anovulatory state also has consequences for the endometrium. Without ovulation, no progesterone is produced by a corpus luteum. The endometrium is therefore exposed to unopposed estrogen, which leads to endometrial hyperplasia and carries an increased long-term risk of endometrial cancer. This is a heavily tested concept: a young woman with PCOS, chronic anovulation, and abnormal uterine bleeding should prompt concern for endometrial pathology.

Additionally, the metabolic derangements in PCOS extend beyond reproduction. Patients are at increased risk for type 2 diabetes, dyslipidemia, metabolic syndrome, and cardiovascular disease, making PCOS a systemic endocrine-metabolic disorder rather than a purely gynecologic condition.

02Classification and Clinical Manifestation

Rotterdam Criteria

Clinical Manifestation

A key point for exams: hyperandrogenism can be either clinical (visible hirsutism, acne, alopecia) or biochemical (elevated free testosterone, elevated DHEA-S). Either form satisfies the Rotterdam criterion. A patient may not appear visibly hirsute but still have elevated androgens on lab work.

03Diagnostic Workup

The best initial step when a young woman presents with oligomenorrhea and signs of androgen excess is to check serum testosterone (total and free) along with a basic hormonal panel (TSH, prolactin, 17-hydroxyprogesterone). The purpose of this initial workup is twofold: confirm biochemical hyperandrogenism and exclude dangerous mimics.

17-hydroxyprogesterone deserves emphasis. Late-onset (non-classic) congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the most commonly tested differential. An early morning 17-OHP level below 200 ng/dL effectively rules this out. If borderline or elevated, an ACTH stimulation test is the confirmatory step. Test-writers love pairing PCOS with this differential.

Transvaginal ultrasound is used to evaluate ovarian morphology. The finding of 12 or more peripheral follicles measuring 2 to 9 mm arranged in a subcapsular pattern ("string of pearls") with increased ovarian volume is classic. However, it is critical to understand that polycystic ovarian morphology alone does not make the diagnosis. Up to 25% of normal women of reproductive age have polycystic-appearing ovaries on ultrasound. The Rotterdam criteria demand at least two of three features, so ultrasound is supportive but never sufficient in isolation.

The LH:FSH ratio of 2:1 or greater is a classic teaching point but is not required for diagnosis. It is supportive when present and helps differentiate PCOS from hypothalamic amenorrhea, where both LH and FSH are low.

For patients with prolonged amenorrhea (more than 6 months without a period) or heavy irregular bleeding, endometrial biopsy or transvaginal ultrasound to assess endometrial thickness should be performed to evaluate for endometrial hyperplasia.

04Management and Treatment

Menstrual Regulation and Hyperandrogenism

The combined oral contraceptive pill is the first-line therapy for women who do not desire pregnancy. The estrogen component increases hepatic SHBG production, which binds free testosterone and lowers bioavailable androgen levels. The progestin component opposes the effect of unopposed estrogen on the endometrium, reducing the risk of endometrial hyperplasia. A COC containing an anti-androgenic progestin (such as drospirenone or cyproterone acetate) provides additional benefit for hirsutism and acne. Improvement in hirsutism takes 6 months or longer because of the long hair growth cycle.

If COCs are contraindicated (history of venous thromboembolism, migraine with aura, active liver disease, smoker over 35), cyclic progestins can be used instead. Medroxyprogesterone acetate 10 mg daily for 10 to 14 days each month induces a withdrawal bleed and protects the endometrium, but it does not address hyperandrogenism.

Hirsutism

For hirsutism that does not adequately respond to 6 months of COC therapy, spironolactone (50 to 200 mg daily) is added. Spironolactone is an aldosterone antagonist that also acts as an androgen receptor blocker and inhibits 5-alpha reductase. It is absolutely contraindicated in pregnancy (teratogenic: feminization of a male fetus), so reliable contraception must be ensured, which is why it is typically prescribed alongside a COC. Monitor potassium levels, as spironolactone can cause hyperkalemia.

Insulin Resistance

Metformin (starting at 500 mg daily, titrated to 1500 to 2000 mg daily) improves insulin sensitivity, lowers circulating insulin, and indirectly reduces ovarian androgen production. It is most beneficial in patients with documented insulin resistance, impaired glucose tolerance, or those who do not tolerate COCs. Metformin alone is not sufficient to treat hyperandrogenism or regulate cycles in most patients, so it is often used as an adjunct. The extended-release formulation reduces gastrointestinal side effects.

Lifestyle modification (caloric restriction and regular exercise targeting a weight loss of 5 to 10% of body weight) can restore ovulatory cycles, improve insulin sensitivity, and lower androgen levels. This is recommended for all overweight or obese patients with PCOS and is considered a foundational intervention.

Fertility

When pregnancy is desired, the approach shifts entirely. COCs and spironolactone must be discontinued. Letrozole (an aromatase inhibitor, 2.5 to 7.5 mg on cycle days 3 to 7) is now the first-line ovulation induction agent, having replaced clomiphene based on evidence showing higher live birth rates and a lower risk of multiple gestations. Clomiphene (50 to 150 mg on cycle days 5 to 9) remains second-line. If both fail, gonadotropin therapy (low-dose FSH injections) or ovarian drilling (laparoscopic electrocautery of the ovarian surface) are next steps. In vitro fertilization is reserved for refractory cases.

Endometrial Protection

Any patient with PCOS who is not on a COC and has prolonged amenorrhea must receive some form of endometrial protection. Options include cyclic progestin withdrawal, a levonorgestrel-releasing IUD, or regular monitoring of endometrial thickness. The clinical concern is progression from endometrial hyperplasia to carcinoma due to chronic unopposed estrogen.

05Differential Diagnosis and Distractors

The most heavily tested differential is non-classic CAH. The vignette will describe a young woman with hirsutism and irregular menses, and the answer choices will include both PCOS and CAH. The discriminator is the 17-hydroxyprogesterone level. If the stem mentions an elevated 17-OHP or includes a clue like "family history of ambiguous genitalia" or "Ashkenazi Jewish descent," think CAH.

Androgen-secreting tumors are distinguished by the tempo and severity. PCOS develops gradually over years starting around menarche. A woman with rapid-onset virilization (over weeks to months) with signs such as voice deepening, clitoromegaly, or male-pattern baldness warrants immediate imaging and has a testosterone level that is usually strikingly elevated.

06Traps and High-Yield Pearls

The most common trap with PCOS questions involves failing to rule out other causes before making the diagnosis. PCOS is a diagnosis of exclusion. Test-writers will present a classic-sounding PCOS vignette but include a subtle lab value (like an elevated 17-hydroxyprogesterone or elevated prolactin) that points to a different diagnosis. Students who jump to PCOS without reviewing the provided lab data will choose the wrong answer.

A second frequent pitfall is confusing first-line fertility treatment. Letrozole has replaced clomiphene as the preferred ovulation induction agent for PCOS. Older resources still list clomiphene as first-line, but current evidence and guidelines favor letrozole for higher ovulation and live birth rates with fewer multiple pregnancies.

Another tested concept: understanding that spironolactone is never used without contraception in women of reproductive age. If a vignette asks for the next step after starting spironolactone for hirsutism, the answer may involve ensuring adequate birth control.

Students also commonly forget the long-term complications. A question may present a woman with known PCOS who has not had a period in over a year and now has irregular vaginal bleeding. The next best step is to evaluate the endometrium (ultrasound to measure endometrial thickness or endometrial biopsy), not simply restart a COC. The core competency being tested here is recognizing the risk of unopposed estrogen leading to endometrial hyperplasia or carcinoma.

Finally, remember that ultrasound findings alone are not diagnostic. A vignette showing polycystic ovaries on imaging in a woman with regular cycles and no hyperandrogenism does not meet Rotterdam criteria. Polycystic morphology is common in normal women and is only meaningful in the right clinical context.

The overarching skill being examined in PCOS questions is the ability to integrate hormonal, metabolic, and reproductive data into a single clinical picture, apply exclusion criteria methodically, and select management based on the patient's primary goal (cycle regulation, cosmetic improvement, or fertility).